ReviewFrontiers in immunology2020
Role of miRNAs in Normal and Myasthenia Gravis Thymus.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Transcriptomic analysis of lncRNA-miRNA-mRNA competing endogenous RNA regulatory networks in radiation-induced mouse thymic degeneration.Immunologic research · 2026Article
- miR-194-5p-mediated suppression of protein tyrosine phosphatase non-receptor type 12 (PTPN12) expression in the thymus enhances immunologic functional restoration in aged mice.European journal of medical research · 2026Article
- Targeted Inhibition of Oncogenic microRNAs miR-21, miR-17, and miR-155 Suppresses Tumor Growth and Modulates Immune Response in Colorectal Cancer.Pharmaceutics · 2026Article
- Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.Frontiers in immunology · 2026Article
- Plasma Biomarkers of Mitochondrial Dysfunction in Patients with Myasthenia Gravis.Medical sciences (Basel, Switzerland) · 2025Article
- Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.Frontiers in immunology · 2025Article
- Ocular myasthenia gravis management.Frontiers in neurology · 2025Review
- Myasthenia gravis: the future is here.The Journal of clinical investigation · 2024Review
- MicroRNA‑155‑5p affects regulatory T cell activation and immunosuppressive function by targeting BCL10 in myasthenia gravis.Experimental and therapeutic medicine · 2024Article
- Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.Frontiers in molecular biosciences · 2024Review
- miRNAs as the important regulators of myasthenia gravis: involvement of major cytokines and immune cells.Immunologic research · 2023Review
- MicroRNAs: master regulators in host-parasitic protist interactions.Open biology · 2022Review
- The LINC00452/miR-204/CHST4 Axis Regulating Thymic Tregs Might Be Involved in the Progression of Thymoma-Associated Myasthenia Gravis.Frontiers in neurology · 2022Article
- Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells.Frontiers in immunology · 2022Review
- Identification of transcriptome alterations in the prefrontal cortex, hippocampus, amygdala and hippocampus of suicide victims.Scientific reports · 2021Article
- Review
- Molecular pathology of thymomas: implications for diagnosis and therapy.Virchows Archiv : an international journal of pathology · 2021Review
- Expression and Clinical Significance of miR-146a and Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) in Myasthenia Gravis Patient Serum.BioMed research international · 2021Article
- Decreased expression of miR-29 family associated with autoimmune myasthenia gravis.Journal of neuroinflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The thymus, a primary lymphoid organ, provides a complex environment essential for the generation of the T-cell repertoire. Thymic alterations occur during life either in the context of thymic involution upon aging or the pathophysiological context of Myasthenia Gravis (MG). These changes involve complicated regulatory networks, in which microRNAs (miRNAs) are key players. Here, we analyzed the role of miRNAs in thymocyte maturation and differentiation sustained by thymic epithelial cells. We compared data from the literature regarding the role of mouse thymic miRNAs and original data obtained from a human thymic miRnome study. We identified a set of highly expressed miRNAs defined as ThymiRs and investigated miRNA expression in infants as compared to adults to determine those associated with human thymic involution. Thymic changes are also frequently observed in MG, an autoimmune disease which results in the production of anti-acetylcholine receptor (AChR) antibodies that lead to muscle weaknesses. Alterations such as thymoma in late-onset MG patients and hyperplasia with ectopic germinal centers (GCs) in early-onset (EOMG) patients are found. Thymic miRNA expression has been studied in AChR-MG patients both in thymoma-associated MG (TAMG) and EOMG, and their function through their mRNA targets investigated. Most of the dysregulated thymic miRNAs in EOMG are associated with GC development, such as miR-7, miR-24, miR-139, miR-143, miR-145, miR-146, miR-150, miR-452, miR-548 or thymic inflammation, such as miR-125b, miR-146, or miR-29. Understanding these pathways may provide therapeutic targets or biomarkers of disease manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.